Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 445 (ZNF445) is a nuclear DNA-binding transcription factor of the KRAB and SCAN domain-containing zinc finger family. It binds to double-stranded methylated DNA at imprinting control regions (ICRs) and coordinates the recruitment of repressive complexes such as KAP1, DNA methyltransferases, and histone methyltransferases[3][4][5]. ZNF445 is critical for the maintenance of parent-specific DNA methylation and gene silencing during early embryonic development, protecting genomic imprints from erasure. It is highly intolerant to loss-of-function, and its deficiency is implicated in multilocus imprinting disorders, transient neonatal diabetes, Temple syndrome, and is a likely cause of some cases of infertility and miscarriage[3][5]. ZNF445 expression is most prominent in early embryonic stages, and also occurs in adult tissues including testis and skeletal muscle[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 445 (ZNF445).